New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Takeaways - MDSpire

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients

While an estimated 95% of “younger” patients diagnosed with Hodgkin lymphoma are still alive and into survivorship within five years of their diagnosis, their long-term health suffers from the aggressive treatment needed to fight the disease.

  • November 10, 2025

Share

  • 1

    The new Phase 3 clinical trial, AHOD2131, aims to reduce long-term treatment complications in Hodgkin lymphoma patients.

  • 2

    Immunotherapy is being incorporated to decrease the intensity of conventional chemotherapy and radiation therapy.

  • 3

    The trial is open to pediatric and adult patients aged 5 to 60 with stage 1 or 2 Hodgkin lymphoma.

  • 4

    The study anticipates that only 15% of patients will require radiation, significantly lower than historical rates.

  • 5

    The trial aims to enroll 1,875 patients over five years and includes correlative studies on treatment response and tolerability.

Original Source(s)

New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients

  • November 10, 2025

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report